PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Pregabalin - Pain (Neuropathic)
PAD Profile : Pregabalin - Pain (Neuropathic)
Keywords :
diabetic neuropathy, postherpetic neuralgia, PHN, neuropathic pain
Brand Names Include :
Lyrica
Traffic Light Status
Status 1 of 2.
Status :
Green (see narrative)
Important
Formulations :
- Capsules
Important Information :
Gabapentin is preferred due to lower potential for misuse.
Pregabalin capsules more cost effective than tablets
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Comments :
No comments returned.
Documents :
Status 2 of 2.
Guidelines
No guidelines returned.
Other Drugs
- Duloxetine hydrochloride
- Amitriptyline hydrochloride
- Gabapentin
- Nortriptyline
- Imipramine hydrochloride
- Dosulepin hydrochloride
- Tramadol hydrochloride
- Capsaicin
Other Indications
Additional Documents
Type
Document
Review Date
Guidelines (National)
Safety Information
01 August 2023
Committee Recommendations
Date
Committee Name
Narrative
03 February 2016
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
Prescribers are reminded to undertake a proportionate risk benefit assessment prior to prescribing Pregabalin or Gabapentin for patients with a known or suspected propensity to misuse.
See Advice for Prescribers document below
Associated BNF Codes
04. Central Nervous System
04.07.03. Neuropathic pain